Nektar Therapeutics (NKTR) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nektar Therapeutics.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.017 Hello, and thank you for standing by. Welcome to the Nectar Therapeutics fourth quarter 00:00:05.017 -- 00:00:10.124 2025 financial results conference call. At this time, all participants 00:00:10.124 -- 00:00:14.810 are in a listen-only mode. After the speaker's presentation, there will be a question 00:00:14.810 -- 00:00:20.057 and answer session. Please be advised that today's conference is being recorded. 00:00:20.057 -- 00:00:24.583 I would now like to hand the conference over to Vivian Wu from Nectar Investor Relations 00:00:24.583 -- 00:00:28.128 to kick things off. Please go ahead. 00:00:28.128 -- 00:00:30.891 Thank you, Crystal, and good afternoon, everyone. 00:00:30.891 -- 00:00:35.175 Thank you for joining us today. Today, you will hear from Howard Robin, our President 00:00:35.175 -- 00:00:39.679 and Chief Executive Officer, Dr. Jonathan Zalewski, our Chief Research and Development 00:00:39.679 -- 00:00:43.683 Officer, and Sandra Gardner, our Chief Financial Officer. 00:00:43.683 -- 00:00:49.129 Dr. Mary Tagliaferri, our Chief Medical Officer, will also be available during the Q&A. 00:00:49.129 -- 00:00:52.492 On today's call, we expect to make forward-looking statements regarding our business, 00:00:52.492 -- 00:00:56.416 including statements regarding the therapeutic potential of and future development plans 00:00:56.416 -- 00:01:01.564 for Respec Aldis-Lukens. the timing and plans for future clinical data presentations, 00:01:01.564 -- 00:01:04.229 and other statements regarding the future of our business. 00:01:04.229 -- 00:01:07.675 Because forward-looking statements relate to the future, they are subject to uncertainties 00:01:07.675 -- 00:01:12.484 and risks that are difficult to predict, and many of which are ou...